Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alessandro Villa
Institution:
Mario Negri Institute for Pharmacological Research
Observed institution:
Mario Negri Institute for Pharmacological Research
ORCID:
0000-0001-5556-5701
Observed ORCID:
0000-0001-5556-5701
OpenAlex ID:
A5022315315
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)
2023
·
Norberto Perico
, Giuseppe Remuzzi
, et al.
·
Journal of the American Society of Nephrology
·
115
Arteriovenous fistula creation with VasQ TM device: A feasibility study to reveal hemodynamic implications
2022
·
Michela Bozzetto
, Luca Soliveri
, et al.
·
The Journal of Vascular Access
·
28
PDF
Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome
2023
·
Federica Casiraghi
, Marta Todeschini
, et al.
·
International Journal of Molecular Sciences
·
9
PDF
Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD
2025
·
Matias Trillini
, Alessandro Villa
, et al.
·
Kidney International Reports
·
6
PDF
Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy
2026
·
Matias Trillini
, Federica Casiraghi
, et al.
·
Kidney International Reports
·
5
PDF
Randomized Controlled Clinical Trial of Allogeneic Mesenchymal Stromal Cell Infusion in Diabetic Kidney Disease
2026
·
Norberto Perico
, Matthew D. Griffin
, et al.
·
Kidney International Reports
·
3
PDF
Glomerular filtration rate estimation in nephrotic patients: creatinine and/or cystatin-C-based equations, or none of them?
2026
·
Fabiola Carrara
, Serenella Valaperta
, et al.
·
Clinical Kidney Journal
PDF
Show more works
View as search
Works count:
8
Citation count:
169
H-index:
5
I10-index:
2
Year
Topic
Type